MA49122A - Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse - Google Patents

Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse

Info

Publication number
MA49122A
MA49122A MA049122A MA49122A MA49122A MA 49122 A MA49122 A MA 49122A MA 049122 A MA049122 A MA 049122A MA 49122 A MA49122 A MA 49122A MA 49122 A MA49122 A MA 49122A
Authority
MA
Morocco
Prior art keywords
peptides
combinations
cancer immunotherapy
intended
peptides intended
Prior art date
Application number
MA049122A
Other languages
English (en)
Inventor
Marco Moreno Di
Sebastian Haen
Daniel Kowalewski
Markus Löffler
Annika Nelde
Hans-Georg Rammensee
Stefan Stevanovic
Nico Trautwein
Juliane Sarah Walz
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA49122A publication Critical patent/MA49122A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
MA049122A 2017-04-10 2018-04-10 Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse MA49122A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483702P 2017-04-10 2017-04-10
DE102017107697 2017-04-10

Publications (1)

Publication Number Publication Date
MA49122A true MA49122A (fr) 2021-03-24

Family

ID=62116819

Family Applications (2)

Application Number Title Priority Date Filing Date
MA049122A MA49122A (fr) 2017-04-10 2018-04-10 Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
MA051170A MA51170A (fr) 2017-04-10 2018-04-10 Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA051170A MA51170A (fr) 2017-04-10 2018-04-10 Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse

Country Status (17)

Country Link
US (3) US20220332760A1 (fr)
EP (2) EP3725327A3 (fr)
JP (2) JP2020516681A (fr)
KR (1) KR20190137829A (fr)
CN (12) CN111533798A (fr)
AU (2) AU2018251839B2 (fr)
BR (1) BR112019020959A2 (fr)
CA (1) CA3059644A1 (fr)
CL (1) CL2019002880A1 (fr)
CO (1) CO2019012077A2 (fr)
CR (3) CR20190508A (fr)
IL (1) IL269741A (fr)
MA (2) MA49122A (fr)
MX (1) MX2019012225A (fr)
PE (1) PE20191711A1 (fr)
PH (1) PH12019502308A1 (fr)
SG (2) SG11201909153UA (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909153UA (en) * 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
BR112019028070A2 (pt) * 2017-07-07 2020-07-14 Immatics Biotechnologies Gmbh peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres
CN111978375B (zh) * 2020-08-28 2022-10-04 深圳市乐土生物医药有限公司 具有细胞毒性t细胞诱导能力的蛋白质或多肽
AU2022277246A1 (en) * 2021-05-18 2024-01-04 Hung, Mien-Chie Vaccine, use thereof and cancer vaccine cocktail
CN114410638B (zh) * 2022-01-24 2023-04-14 郑州大学 一种核酸适配体及其在食管癌检测中的应用
CN117586344A (zh) * 2022-08-12 2024-02-23 上海交通大学医学院附属瑞金医院 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
WO2024077601A1 (fr) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Vaccins peptidiques contre le gliome et leurs utilisations
CN116426532B (zh) * 2023-06-08 2023-09-12 时夕(广州)生物科技有限公司 一种靶向适配体及其应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DD147855A5 (de) 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (fr) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
CA2383562A1 (fr) * 1999-08-26 2001-03-01 Keith M. Skubitz Peptides capables de moduler la fonction des membres de la famille cd66 (ceacam)
WO2001042270A1 (fr) * 1999-12-10 2001-06-14 Epimmune Inc. Induction de reponses immunes cellulaires a l'antigene carcinoembryonnaire a l'aide des compositions renfermant des peptides et des acides nucleiques
EP1294748B1 (fr) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Complexes majeurs d'histocompatibilite monocatenaires de classe 1, constructions les codant et leurs methodes de production
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
JP4439808B2 (ja) 2000-06-05 2010-03-24 アルター・バイオサイエンス・コーポレーション Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
US7553939B2 (en) * 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (fr) 2002-02-20 2003-08-28 Dyax Corp. Ligands de liaison au complexe mhc-peptide
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2005537800A (ja) * 2002-09-06 2005-12-15 マンカインド コーポレイション エピトープ配列
CN100347191C (zh) 2002-10-02 2007-11-07 霍夫曼-拉罗奇有限公司 新mhcⅱ相关肽
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
JP4975324B2 (ja) 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
CA2511775A1 (fr) * 2002-12-10 2004-06-24 Epimmune Inc. Peptides diriges contre des antigenes associes aux tumeurs hla-a1, a2 -a3,-a24,-b7, et -b44 et compositions
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
AU2004219820B2 (en) * 2003-03-10 2008-06-12 Japan Science And Technology Agency Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
JP4505749B2 (ja) 2003-05-30 2010-07-21 日本新薬株式会社 Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
CN101035561A (zh) * 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
WO2006113747A2 (fr) * 2005-04-19 2006-10-26 Prediction Sciences Llc Marqueurs diagnostiques du traitement et de l'evolution du cancer du sein et leurs methodes d'utilisation
ES2334936T3 (es) 2005-04-20 2010-03-17 F. Hoffmann-La Roche Ag Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos.
ATE512160T1 (de) * 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
ES2341295T3 (es) * 2005-09-05 2010-06-17 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
CA2642994C (fr) * 2006-02-24 2015-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides immunogenes page-4 et leurs methodes d'utilisation
US20130332133A1 (en) * 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
EP2567707B1 (fr) * 2007-07-27 2016-10-05 Immatics Biotechnologies GmbH Composition de peptides associés à des tumeurs et vaccin anti-cancer connexe
CN103911358B (zh) * 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
WO2009075883A2 (fr) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Biomarqueur de cancer de glycoprotéine
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
CN101648012A (zh) * 2008-04-24 2010-02-17 伊玛提克斯生物技术有限公司 结合到人类白细胞抗原(hla)ⅰ类或ⅱ类分子上用作疫苗的肿瘤相关肽新制剂
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
WO2011035433A1 (fr) * 2009-09-23 2011-03-31 University Health Network Souches sélectionnées sur des milieux de croissance exempts de sérum pour analyse protéomique de biomarqueurs du cancer du poumon
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (fr) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Anticorps qui se lient à des ligands de récepteurs de lymphocytes t solubles
WO2013057586A1 (fr) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions et procédés de production de récepteurs solubles des lymphocytes t
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2808392A1 (fr) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP6432114B2 (ja) * 2014-12-25 2018-12-05 有限会社イムノ 免疫応答を誘導するための薬剤
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA45352A (fr) * 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
US20170136108A1 (en) * 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
WO2018189148A1 (fr) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
SG11201909153UA (en) * 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法

Also Published As

Publication number Publication date
CA3059644A1 (fr) 2018-10-18
CN111499714A (zh) 2020-08-07
AU2022221503A1 (en) 2022-09-22
IL269741A (en) 2019-11-28
CR20210160A (es) 2021-04-26
EP3725327A3 (fr) 2021-01-20
EP3609530A1 (fr) 2020-02-19
JP7551823B2 (ja) 2024-09-17
US20220332760A1 (en) 2022-10-20
CN111533798A (zh) 2020-08-14
CN111548406A (zh) 2020-08-18
AU2018251839A1 (en) 2019-11-28
CO2019012077A2 (es) 2020-04-01
CN111533796A (zh) 2020-08-14
JP2020516681A (ja) 2020-06-11
SG11201909153UA (en) 2019-10-30
CR20210159A (es) 2021-05-21
CN111499715A (zh) 2020-08-07
CN111528539A (zh) 2020-08-14
BR112019020959A2 (pt) 2020-05-05
EP3725327A2 (fr) 2020-10-21
US20230346837A1 (en) 2023-11-02
PH12019502308A1 (en) 2020-10-26
PE20191711A1 (es) 2019-11-28
CN111499716A (zh) 2020-08-07
MX2019012225A (es) 2019-12-09
CN110494157A (zh) 2019-11-22
SG10202107869QA (en) 2021-08-30
CR20190508A (es) 2020-01-08
CN111647062A (zh) 2020-09-11
US20220356208A1 (en) 2022-11-10
CN111548405A (zh) 2020-08-18
KR20190137829A (ko) 2019-12-11
US11560405B2 (en) 2023-01-24
MA51170A (fr) 2020-10-21
AU2018251839B2 (en) 2022-06-30
CL2019002880A1 (es) 2020-03-13
JP2023100687A (ja) 2023-07-19
CN111548404A (zh) 2020-08-18
CN111533797A (zh) 2020-08-14

Similar Documents

Publication Publication Date Title
MA49122A (fr) Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
IL297617B1 (en) Multimeric polypeptides modulate t cells and methods for their use
MA44999A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre diverses tumeurs
MA42494A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
IL261401A (en) T-cell modulatory multimeric polypeptides and methods of using them
IL272069A (en) Dosage regimens of ANTI-LAG-3 antibodies and their uses
HK1257056A1 (zh) 抗dll3抗體藥物綴合物以及使用方法
IL262403A (en) Multimeric polypeptides modulate t cells and methods for their use
IL261402A (en) T cell modulatory multimeric polypeptides and methods of using them
MA50542A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
ZA201901207B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
DK3443009T3 (da) Anti-tim-3-antistoffer og sammensætninger
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
IL263788A (en) Anti-peptide n3pglu amyloid beta antibodies and their uses
ZA201903657B (en) Ras protein degradation inducing molecule and pharmaceutical composition
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
DK3503885T3 (da) Farmaceutisk præparat og fremgangsmåder til anvendelse heraf
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf
DK3423042T3 (da) Lyofiliseret farmaceutisk formulering og anvendelse deraf
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante
DK3438118T3 (da) Peptidderivat og anvendelse deraf
GB201619818D0 (en) Anti-idiotypic antibodies and uses thereof
EA202190896A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
BR112018000205A2 (pt) oxiesteróis e métodos de uso destes